Soligenix Q2 10-Q Flags Going Concern, Nasdaq Delisting Risk, and Heavy ATM Dilution
SNGX sits 39% above its 52-week low of $0.28.
Summary
Soligenix's Q2 2026 10-Q reveals a going concern warning, Nasdaq delisting risk, and massive ATM-driven dilution — shares outstanding more than doubled in six months.
Key Events · Financing and Capital Events · SNGX
-
Going Concern Warning
Management expresses substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital, strategic transactions, or government funding — none of which are committed.
-
Nasdaq Delisting Risk
The company received a delisting notice on June 10, 2026, for failing to maintain a $1.00 minimum bid price. It has until December 7, 2026, to regain compliance, likely requiring a reverse stock split.
-
Massive ATM-Driven Dilution
In H1 2026, the company sold 11.5M shares via its ATM for $6.0M in net proceeds, increasing shares outstanding from 10.1M to 21.6M — a 114% increase. An additional 128,000 shares were sold in July at $0.40/share.
-
Cash Runway and Remaining ATM Capacity
Cash and equivalents stand at $9.8M as of June 30, 2026, providing runway into Q2 2028. However, only $2.4M remains on the ATM facility, and the company warns it may need to delay, reduce, or eliminate development efforts if additional capital is not secured.
Analysis · SNGX · Life Sciences
Incorporated into this prospectus supplement, Soligenix's Q2 2026 10-Q warns of a going concern, Nasdaq delisting risk, and massive ATM-driven dilution. During the first half of 2026, the company sold $6.2M in shares through its ATM, ballooning shares outstanding from 10.1M to 21.6M — a 114% increase. With only $2.4M remaining on the ATM and a cash runway into Q2 2028, management cautions that survival may hinge on securing additional capital. The stock trades at $0.39, far below the $1.00 Nasdaq minimum, and a reverse split proposal is pending. This filing confirms the company is fighting for its listing and its life.
At the time of this filing, SNGX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.5M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.